1
|
Weber M, Sediri H, Felgenhauer U, Binzen I, Bänfer S, Jacob R, Brunotte L, García-Sastre A, Schmid-Burgk JL, Schmidt T, Hornung V, Kochs G, Schwemmle M, Klenk HD, Weber F. Influenza virus adaptation PB2-627K modulates nucleocapsid inhibition by the pathogen sensor RIG-I. Cell Host Microbe 2015; 17:309-319. [PMID: 25704008 PMCID: PMC4359673 DOI: 10.1016/j.chom.2015.01.005] [Citation(s) in RCA: 101] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2014] [Revised: 10/24/2014] [Accepted: 01/05/2015] [Indexed: 12/16/2022]
Abstract
The cytoplasmic RNA helicase RIG-I mediates innate sensing of RNA viruses. The genomes of influenza A virus (FLUAV) are encapsidated by the nucleoprotein and associated with RNA polymerase, posing potential barriers to RIG-I sensing. We show that RIG-I recognizes the 5'-triphosphorylated dsRNA on FLUAV nucleocapsids but that polymorphisms at position 627 of the viral polymerase subunit PB2 modulate RIG-I sensing. Compared to mammalian-adapted PB2-627K, avian FLUAV nucleocapsids possessing PB2-627E are prone to increased RIG-I recognition, and RIG-I-deficiency partially restores PB2-627E virus infection of mammalian cells. Heightened RIG-I sensing of PB2-627E nucleocapsids correlates with previously established lower affinity of 627E-containing PB2 for nucleoprotein and is increased by further nucleocapsid instability. The effect of RIG-I on PB2-627E nucleocapsids is independent of antiviral signaling, suggesting that RIG-I-nucleocapsid binding alone can inhibit infection. These results indicate that RIG-I is a direct avian FLUAV restriction factor and highlight nucleocapsid disruption as an antiviral strategy.
Collapse
Affiliation(s)
- Michaela Weber
- Institute for Virology, Philipps-University Marburg, D-35043 Marburg, Germany
| | - Hanna Sediri
- Institute for Virology, Philipps-University Marburg, D-35043 Marburg, Germany
| | - Ulrike Felgenhauer
- Institute for Virology, Philipps-University Marburg, D-35043 Marburg, Germany
| | - Ina Binzen
- Institute for Virology, Philipps-University Marburg, D-35043 Marburg, Germany
| | - Sebastian Bänfer
- Department of Cell Biology and Cell Pathology, Philipps-University Marburg, D-35043 Marburg, Germany
| | - Ralf Jacob
- Department of Cell Biology and Cell Pathology, Philipps-University Marburg, D-35043 Marburg, Germany
| | - Linda Brunotte
- Institute for Virology, University Medical Center, D-79008 Freiburg, Germany
| | - Adolfo García-Sastre
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Jonathan L Schmid-Burgk
- Institute of Molecular Medicine, University Hospital, University of Bonn, D-53127 Bonn, Germany
| | - Tobias Schmidt
- Institute of Molecular Medicine, University Hospital, University of Bonn, D-53127 Bonn, Germany
| | - Veit Hornung
- Institute of Molecular Medicine, University Hospital, University of Bonn, D-53127 Bonn, Germany
| | - Georg Kochs
- Institute for Virology, University Medical Center, D-79008 Freiburg, Germany
| | - Martin Schwemmle
- Institute for Virology, University Medical Center, D-79008 Freiburg, Germany
| | - Hans-Dieter Klenk
- Institute for Virology, Philipps-University Marburg, D-35043 Marburg, Germany
| | - Friedemann Weber
- Institute for Virology, Philipps-University Marburg, D-35043 Marburg, Germany.
| |
Collapse
|